Novel Treatments in HER2-Positive Breast Cancer
OncLive interviewed experts on novel treatments in HER2-positive breast cancer.
Dr. Thompson on Sequencing Strategies in HER2+ Breast Cancer
Forrest Thompson, MD, discusses sequencing strategies in HER2-positive breast cancer.
Dr. Hurvitz on Treatment Options in Early-Stage HER2+ Breast Cancer
Sara A. Hurvitz, MD, discusses available treatment options in early-stage HER2-positive breast cancer.
Dr. Olajide on Managing Risk of Interstitial Lung Disease With Trastuzumab Deruxtecan in Breast Cancer
Oludamilola (Lola) A. Olajide, MD, discusses managing the risk of interstitial lung disease with fam-trastuzumab deruxtecan-nxki in breast cancer.
Dr. Krill-Jackson on the Potential Utility of Trastuzumab Deruxtecan in Metastatic Breast Cancer
Elisa Krill-Jackson, MD, discusses the potential future utility of fam-trastuzumab deruxtecan-nxki in the treatment of patients with metastatic breast cancer.
Dr. Hurvitz on Additional Research Needed With Trastuzumab Deruxtecan in HER2+ Breast Cancer
Sara A. Hurvitz, MD, discusses the need for additional research with fam-trastuzumab deruxtecan-nxki in HER2-positive breast cancer.
Continued ADC Development in NSCLC Necessitates Improved Knowledge of Mechanisms and Biomarker Optimization
Neoadjuvant vs Perioperative Immune Checkpoint Blockade in Resectable NSCLC: How Do We Choose?
EGFR TKI–Based Combinations May Revolutionize Frontline EGFR+ NSCLC Management
Dr Olazagasti on a Case-Based Discussion of ALK-Mutated NSCLC Treatment
2 Commerce Drive Cranbury, NJ 08512